BioMarin也迅速跟进迭代研发，其升级版在研产品BMN333同样旨在实现周剂注射。早期临床结果显示BMN333的AUC水平高于其他长效CNP研究的3倍以上，公司研发主管Greg Friberg表示该药对标的正是TransCon-CNP。
"debacle," so they couldn't have been great.
，详情可参考搜狗输入法下载
cd confusable-vision
It requires the allocation+copy only in the case that we’ve exclusively